News

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.
The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...
Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...
Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...
Novartis reported an impressive 11% increase in sales in constant currency, accompanied by a 21% rise in core operating income for Q2 2025. This growth underscores the company’s strong financial ...
Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...
The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title. Swiss pharmaceutical giant Novartis AG ...
Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...
Novartis (SIX:NOVN) reported a 24% surge in Q2 net income to $4 billion, driven by robust demand for key therapies like Kisqali, Entresto, and Kesimpta. Earnings per share rose 29% to $2.07, supported ...
Medicare covers Leqvio when a doctor or healthcare professional prescribes it. Out-of-pocket expenses may apply. Read more.
Leqvio is a brand-name prescription medication containing the active ingredient inclisiran. A healthcare professional administers it as an injection under the skin. Original Medicare Part B covers ...
LEQVIO marks a significant advancement in hypercholesterolemia management, particularly for patients not achieving target LDL-C levels despite maximally tolerated statin therapy. As the first FDA ...